Condition: T-cell-prolymphocytic Leukemia · Cutaneous T-Cell Lymphoma Refractory · Sponsor: Jonsson Comprehensive Cancer Center
This is an open-label, phase I/II study of duvelisib in combination with Venetoclax for patients with relapsed/refractory NHL. Duvelisib is an FDA approved, marketed product used to treat certain patients with leukemia and lymphoma and Venetoclax, which is approved for treatment of certain patients with acute myeloid leukemia. The combination of these two drugs is experimental. Experimental means that it is not approved by the United States Food and Drug Administration (FDA). The researchers want to find out how safe it is to combine these drugs and how well this combination can work for your cancer.
This description comes directly from the study's public registry record.
Vladimir Bonhomme · 310-794-6500 · VBonhomme@mednet.ucla.edu
Vanessa Crowell · vcrowell@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| David Geffen School of Medicine at the University of California at Los Angeles | Los Angeles, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06810778